Effect of Topical ucb 28754 on Rhinitis Provoked by Intranasal Histamine and Ascaris Suum in the Monkey

Author： Tanner Ernest Choung Ji Tae Swarts J. De Vos Christine Fireman Philip

ISSN： 1539-6290

Source： American Journal of Rhinology, Vol.10, Iss.1, 1996-01, pp. : 45-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

A monkey model was used to evaluate intranasal ucb-28754, a newly developed H₁ antagonist in attenuating nasal obstruction following intranasal challenge with either histamine or Ascaris in a dose response protocol. Nasal patency was measured with computer assisted anterior rhinomanometry. Eight female, feral, Ascaris sensitive, juvenile cynomolgus monkeys were pretreated with 100 ul of 0.075% ucb-28754 or placebo in a crossover study protocol before intranasal histamine provocation. Three of the animals also received 100 ul of 0.075% or 0.3% ucb-28754 or placebo before intranasal Ascaris challenge. Statistically significant (P < 0.05) improvement was observed for the ucb-28754 treated monkeys in nasal conductance and in mean nasal work/L following histamine challenge. Pharmacologic efficacy (50% reduction of nasal obstruction) was achieved for the medication on three of four histamine dosages. In the Ascaris challenged animals, pharmacologic efficacy was achieved for four of five doses for the animals receiving 0.075% ucb-28754 and two of five doses when they were pretreated with 0.3% ucb-28754. Measurement of heart rate, respiratory rate, and blood pressure, as well as visual examination of the monkeys indicated that ucb-28754 had no adverse effects. These studies indicate that ucb-28754 administered intranasally is a potentially safe and effective antihistamine in this monkey experimental model.